[{"orgOrder":0,"company":"Eyenovia","sponsor":"National Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Private Placement","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ National Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ National Securities Corporation"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Atropine","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Not Applicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Arctic Vision","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Atropine","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Eye Drop","sponsorNew":"Eyenovia \/ Arctic Vision","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Arctic Vision"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Atropine","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Not Applicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Bausch Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Atropine","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Eye Drop","sponsorNew":"Eyenovia \/ Bausch Health","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Bausch Health"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tropicamide","moa":"Muscarinic M3 receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Eyenovia \/ Not Applicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Not Applicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Arctic Vision","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Eyenovia","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Eyenovia"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tropicamide","moa":"Muscarinic M3 receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Eyenovia \/ Not Applicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Arctic Vision","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eyenovia \/ Eyenovia","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Eyenovia"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Tropicamide","moa":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Eyenovia \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"11","companyTruncated":"Eyenovia \/ Avenue Venture Opportunities Fund"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tropicamide","moa":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Eyenovia \/ Not Applicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tropicamide","moa":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Eyenovia \/ Not Applicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Phenylephrine Hydrochloride","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eyenovia \/ Not Applicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Formosa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Eyenovia \/ Eyenovia","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Eyenovia"},{"orgOrder":0,"company":"Eyenovia","sponsor":"William Blair","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eyenovia","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Suspension","sponsorNew":"Eyenovia \/ William Blair","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ William Blair"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Atropine","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Eyenovia \/ Eyenovia","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Eyenovia"},{"orgOrder":0,"company":"Eyenovia","sponsor":"NovaBay Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Eyenovia \/ Eyenovia","highestDevelopmentStatusID":"12","companyTruncated":"Eyenovia \/ Eyenovia"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tropicamide","moa":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Eyenovia \/ Not Applicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"SENJU PHARMACEUTICAL CO LTD","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Fonadelpar","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Eyenovia \/ SENJU PHARMACEUTICAL CO LTD","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ SENJU PHARMACEUTICAL CO LTD"},{"orgOrder":0,"company":"Eyenovia","sponsor":"SGN Nanopharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Cyclosporine","moa":"","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Eyenovia \/ SGN Nanopharma","highestDevelopmentStatusID":"3","companyTruncated":"Eyenovia \/ SGN Nanopharma"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"","sponsorNew":"Eyenovia \/ Dawson James Securities","highestDevelopmentStatusID":"12","companyTruncated":"Eyenovia \/ Dawson James Securities"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Eyenovia","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"","sponsorNew":"Eyenovia \/ Dawson James Securities","highestDevelopmentStatusID":"12","companyTruncated":"Eyenovia \/ Dawson James Securities"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Eyenovia","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"","sponsorNew":"Eyenovia \/ Dawson James Securities","highestDevelopmentStatusID":"12","companyTruncated":"Eyenovia \/ Dawson James Securities"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Eyenovia \/ Alliance Global Partners","highestDevelopmentStatusID":"12","companyTruncated":"Eyenovia \/ Alliance Global Partners"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Formosa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Eyenovia \/ Eyenovia","highestDevelopmentStatusID":"12","companyTruncated":"Eyenovia \/ Eyenovia"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eyenovia \/ Not Applicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Chardan Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Tropicamide","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Eyenovia \/ Chardan Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Eyenovia \/ Chardan Healthcare"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Atropine","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Eyenovia
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
